The HER2 CISH pharmDx™ Kit in the assessment of breast cancer patients for anti-HER2 treatment

Expert Review of Molecular Diagnostics

Volumn 13, Issue 3, 2013, Pages 233-242

  Foged, Niels T ^a   Brügmann, Anja ^b   Jørgensen, Jan T ^c  

^a Visiopharm A S   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c Dx Rx Institute   (Denmark)

Author keywords

breast cancer; chromogenic in situ hybridization; companion diagnostics; human epidermal growth factor receptor 2; in situ hybridization

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; NERATINIB; PERTUZUMAB; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CENTROMERE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; LIMIT OF QUANTITATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RECURRENCE RISK; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHROMOGENIC COMPOUNDS; DIAGNOSTIC TEST APPROVAL; FEMALE; HUMANS; IN SITU HYBRIDIZATION; RECEPTOR, ERBB-2;

EID: 84876131881     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.13.6     Document Type: Article

References (57)

1. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14(4), 320-368 (2009
2. Piccart-Gebhart MJ, Procter M, Leyland- Jones B et al.; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1659-1672 (2005
3. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673-1684 (2005
4. Slamon D, Eiermann W, Robert N et al.; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2- positive breast cancer. N. Engl. J. Med. 365(14), 1273-1283 (2011
5. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001
6. Bang YJ, Van Cutsem E, Feyereislova A et al.; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase 3, open-label, randomised controlled trial. Lancet 376(9742), 687-697 (2010
7. Baselga J, Cortes J, Kim SB et al.; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366(2), 109-119 (2012
8. Burris HA 3rd, Rugo HS, Vukelja SJ et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J. Clin. Oncol. 29(4), 398-405 (2011
9. Miyako H, Kametani Y, Katano I et al. Antitumor effect of new HER2 peptide vaccination based on B cell epitope. Anticancer Res. 31(10), 3361-3368 (2011
10. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat. Rev. Clin. Oncol. 9(1), 16-32 (2012
11. Shojaei S, Gardaneh M, Rahimi Shamabadi A. Target points in trastuzumab resistance. Int. J. Breast Cancer 2012, 761917 (2012
12. Jorgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology 78(1), 26-33 (2010
13. Barok M, Tanner M, Koninki K, Isola J. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res. 13(2), R46 (2011
14. Burstein HJ, Sun Y, Dirix LY et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J. Clin. Oncol. 28(8), 1301-1307 (2010
15. Lin NU, Winer EP, Wheatley D et al. A Phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res. Treat. 133(3), 1057-1065 (2012
16. Winther H, Jorgensen JT. Drug-diagnostic co-development in cancer. Pharmaceutical Med. 24(6), 363-375(2010
17. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al.; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354(8), 809-820 (2006
18. Francis GD, Jones MA, Beadle GF, Stein SR. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome. Diagn. Mol. Pathol. 18(2), 88-95 (2009
19. Wolff AC, Hammond ME, Schwartz JN et al.; American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25(1), 118-145 (2007
20. Jorgensen JT, Moller S, Rasmussen BB, Winther H, Schonau A, Knoop A. High concordance between two companion diagnostics tests: a concordance study between the HercepTest and the HER2 FISH pharmDx kit. Am. J. Clin. Pathol. 136(1), 145-151 (2011
21. Middleton LP, Price KM, Puig P et al. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases. Arch. Pathol. Lab. Med. 133(5), 775-780 (2009
22. Yaziji H, Goldstein LC, Barry TS et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291(16), 1972-1977 (2004
23. Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J. Clin. Oncol. 22(5), 854-863 (2004
24. Lehmann-Che J, Amira-Bouhidel F, Turpin E et al. Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches. Br. J. Cancer 104(11), 1739-1746 (2011
25. Mollerup J, Henriksen U, Muller S, Schonau A. Dual color chromogenic in situ hybridization for determination of HER2 status in breast cancer: a large comparative study to current state of the art fluorescence in situ hybridization. BMC Clin. Pathol. 12, 3 (2012
26. Giltnane JM, Molinaro A, Cheng H et al. Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer. Arch. Pathol. Lab. Med. 132(10), 1635-1647 (2008
27. Brugmann A, Sorensen BS. Identifying responders to trastuzumab therapy in breast cancer. Future Oncol. 7(6), 767-773 (2011
28. Ellis LM, Hicklin DJ. Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin. Cancer Res. 15(24), 7471-7478 (2009
29. Mittendorf EA, Wu Y, Scaltriti M et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin. Cancer Res. 15(23), 7381-7388 (2009
30. Niikura N, Liu J, Hayashi N et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J. Clin. Oncol. 30(6), 593-599 (2012
31. Garcia-Caballero T, Grabau D, Green AR et al. Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens. Histopathology 56(4), 472-480 (2010
32. Wilking U, Karlsson E, Skoog L et al. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res. Treat. 125(2), 553-561 (2011
33. Tanner M, Gancberg D, Di Leo A et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am. J. Pathol. 157(5), 1467-1472 (2000
34. Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod. Pathol. 15(6), 657-665 (2002
35. Dandachi N, Dietze O, Hauser-Kronberger C. Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab. Invest. 82(8), 1007-1014 (2002
36. Gupta D, Middleton LP, Whitaker MJ, Abrams J. Comparison of fluorescence and chromogenic in situ hybridization for detection of HER2/neu oncogene in breast cancer. Am. J. Clin. Pathol. 119(3), 381-387 (2003
37. Park K, Kim J, Lim S, Han S, Lee JY. Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray. Mod. Pathol. 16(9), 937-943 (2003
38. Arnould L, Denoux Y, MacGrogan G et al. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br. J. Cancer 88(10), 1587-1591 (2003
39. Isola J, Tanner M, Forsyth A, Cooke TG, Watters AD, Bartlett JM. Interlaboratory comparison of HER2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin. Cancer Res. 10(14), 4793-4798 (2004
40. Hauser-Kronberger C, Dandachi N. Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer. J. Mol. Histol. 35(6), 647-653 (2004
41. Bhargava R, Lal P, Chen B. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization? Am. J. Clin. Pathol. 123(2), 237-243 (2005
42. Gong Y, Gilcrease M, Sneige N. Reliability of chromogenic in situ hybridization for detecting HER2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility. Mod. Pathol. 18(8), 1015-1021 (2005
43. Li-Ning-T E, Ronchetti R, Torres-Cabala C, Merino MJ. Role of chromogenic in situ hybridization (CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH. Int. J. Surg. Pathol. 13(4), 343-351 (2005
44. Loring P, Cummins R, O'Grady A, Kay EW. HER2 positivity in breast carcinoma: a comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization. Appl. Immunohistochem. Mol. Morphol. 13(2), 194-200 (2005
45. Saez A, Andreu FJ, Segui MA et al. HER2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer - a study of two hundred cases. Breast 15(4), 519-527 (2006
46. Hanna WM, Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod. Pathol. 19(4), 481-487 (2006
47. van de Vijver M, Bilous M, Hanna W et al. Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study. Breast Cancer Res. 9(5), R68 (2007
48. Cayre A, Mishellany F, Lagarde N, Penault-Llorca F. Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification. Breast Cancer Res. 9(5), R64 (2007
49. Sinczak-Kuta A, Tomaszewska R, Rudnicka-Sosin L, Okon K, Stachura J. Evaluation of HER2/neu gene amplification in patients with invasive breast carcinoma. Comparison of in situ hybridization methods. Pol. J. Pathol. 58(1), 41-50 (2007
50. Carbone A, Botti G, Gloghini A et al. Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists. J. Mol. Diagn. 10(6), 527-536 (2008
51. Pothos A, Plastira K, Plastiras A, Vlachodimitropoulos D, Goutas N, Angelopoulou R. Comparison of chromogenic in situ hybridisation with fluorescence in situ hybridisation and immunohistochemistry for the assessment of HER-2/neu oncogene in archival material of breast carcinoma. Acta Histochem. Cytochem. 41(3), 59-64 (2008
52. Gong Y, Sweet W, Duh YJ et al. Chromogenic in situ hybridization is a reliable method for detecting HER-2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. Am. J. Clin. Pathol. 131(4), 490-497 (2009
53. Pedersen M, Rasmussen BB. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER-2 gene amplification in breast cancer. Diagn. Mol. Pathol. 18(2), 96-102 (2009
54. Brugmann A, Lelkaitis G, Nielsen S, Jensen KG, Jensen V. Testing HER-2 in breast cancer: a comparative study on BRISH, FISH, and IHC. Appl. Immunohistochem. Mol. Morphol. 19(3), 203-211 (2011
55. Gruver AM, Peerwani Z, Tubbs RR. Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma. J. Clin. Pathol. 63(3), 210-219 (2010
56. Foged NT, Jensen B, Mygind H et al. Automated scoring of brightfield ISH by quantitative analysis of whole slide images of tumor sections. Abstract P048, APMIS 120(Suppl. 134), 18-39 (2012). http://onlinelibrary.wiley.com/doi/10. 1111/j.1600-0463.2012.02894.x/pdf (Accessed 16 September 2012
57. Muller S, Matthiesen SH, Nielsen KV. Preparation of FFPE Tissue Slides for Solid Tumor FISH Analysis. In: Education Guide. Immunohistochemical (IHC) Staining Methods. Kumar GL, Rudbeck L (Eds). Dako North America, CA, USA, 67-74 (2009). www.dako.com/08002-ihc-staining- methods-5ed.pdf (Accessed 16 September 2012